Skip to main content

Table 1 Ongoing clinical trials of tyrosine kinase inhibitors for lung cancer in China

From: Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

Agents

Location(s)

Identifier

Phase

PI in China

Indication

Intervention/content

Status in China

Targeting EGFR pathway

 Afatinib

I

NCT01953913

3

Yi-long Wu

Without history of EGFR TKI treatment

Afatinib efficacy in NSCLC with EGFR mutation(s)

Recruiting

 Icotinib

D

NCT02714010

3

Li-kun Chen

Without history of EGFR TKI treatment

WBI concurrent with EGFR TKI vs EGFR TKI

Recruiting

 Epitinib

D

NCT02590952

1

Yi-long Wu

Without history of EGFR TKI treatment/developed brain lesions during TKI therapy

Pharmacokinetics, safety, and tolerability in solid tumors

Recruiting

 Hemay020

D

NCT02467569

1

Hai-ying Wu

Second-line and beyond

Pharmacokinetics, safety, and tolerability in solid tumors

Recruiting

Targeting T790M pathway

 Osimertinib

I

NCT02296125

3

Yi-long Wu

First-line

Osimertinib vs EGFR TKI in advanced NSCLC

Active, not recruiting

 Avitinib

D

NCT02330367

1/2

Yi-long Wu

Second-line and beyond

Safety, tolerability, pharmacokinetics, and efficacy in T790M-positive advanced NSCLC

Recruiting

 Alflutinib

D

NCT02973763

1

Yuan-kai Shi

Second-line and beyond

Pharmacokinetics, safety, and tolerability in NSCLC after progression on prior EGFR TKI

Not yet recruiting

Targeting HER2 pathway

 Afatinib

I

NCT02597946

2

Cai-cun Zhou

Second-line and beyond

Efficacy in HER2 mutation NSCLC after chemotherapy

Recruiting

 Pyrotinib

D

NCT02535507

2

Cai-cun Zhou

Third-line and beyond

Efficacy in HER2 mutation advanced NSCLC

Recruiting

 Allitinib

D

CTR20150258

2

Yi-long Wu

Second-line and beyond

Safety and efficacy in uncommon EGFR mutant or HER2 mutation/amplification NSCLC

Recruiting

Targeting ALK pathway

 Alectinib

I

NCT02838420

3

Cai-cun Zhou

First-line

Alectinib vs crizotinib in Asian patients NSCLC

Recruiting

 CT-707

D

NCT02695550

1

Yuan-kai Shi

Second-line and beyond

Pharmacokinetics, safety, and tolerability in ALK-positive NSCLC

Recruiting

 Ensartinib

D

NCT02959619

1

Li Zhang

Without history of ALK TKI treatment except crizotinib

Pharmacokinetics, safety, and tolerability in ALK-positive NSCLC

Not yet recruiting

 SAF-189s

D

CTR20160340

1/2

Yi-long Wu

Second-line and beyond

Safety, tolerability, pharmacokinetics, and efficacy in ALK-positive NSCLC

Recruiting

Targeting c-MET pathway

 INC280

I

NCT02276027

2

Yi-long Wu

Without history of c-MET TKI treatment

INC280 in NSCLC with c-MET gene alteration

Recruiting

 Volitinib

D

NCT02374645

1

Jin-ji Yang

Second-line

Volitinib in combination with gefitinib in EGFR-mutated, c-MET-alternated NSCLC after progress on EGFR TKI

Recruiting

 Bozitinib

D

NCT02896231

1

Yi-long Wu

Without history of c-MET/HGF inhibitor treatment

Safety, tolerability, and pharmacokinetics in MET-positive advanced NSCLC

Recruiting

 BPI-9016M

D

NCT02929290

1

Yuan-kai Shi

Second-line and beyond

Safety, efficacy, and pharmacokinetics in c-MET dysregulated advanced NSCLC

Not yet recruiting

Targeting VEGFR pathway

 Fruquintinib

D

NCT02976116

2

Jian-ying Zhou

First-line

Fruquintinib in combination with gefitinib in non-squamous NSCLC with activating EGFR mutation

Recruiting

  

NCT02691299

2

Jian-ying Zhou

Third-line

Placebo-controlled in advanced non-squamous NSCLC

Recruiting

 Apatinib

D

NCT02824458

3

Hong-yun Zhao

First-line

Gefitinib in combination with apatinib or placebo in EGFR mutation-positive advanced non-squamous NSCLC

Recruiting

  

NCT02332512

3

Li Zhang

Third/fourth-line

Apatinib in advanced non-squamous NSCLC harboring wild-type EGFR

Recruiting

 Famitinib

D

NCT02766140

3

Cai-cun Zhou

Second-line

Famitinib plus docetaxel compared to placebo plus docetaxel in advanced or metastatic or recurrent non-squamous NSCLC

Recruiting

 Endostar

D

NCT02001168

3

Zuo-liang Pang

Postoperative adjuvant

Comparison of postoperative adjuvant chemotherapy with/without Rh-endostat in phase Ib NSCLC

Active, not recruiting

 Anlotinib

D

NCT03059797

2

Ying Cheng

Third-line and beyond

Compare the efficacy and safety of anlotinib vs placebo in SCLC

Recruiting

Targeting RET pathway

 Apatinib

D

NCT02540824

2

Cai-cun Zhou

Second-line and beyond

Efficacy and safety of apatinib as a single agent in RET fusion gene-positive NSCLC

Recruiting

  

NCT02780778

2/3

Zhan-yu Pan

Second-line

Apatinib plus docetaxel in advanced non-squamous NSCLC

Recruiting

Targeting ROS-1 pathway

 Crizotinib

I

NCT01945021

2

Jin-ji Yang

First-line or no more than third-line treatment

Safety and efficacy of crizotinib in East Asian patients with ROS1-positive, ALK-negative advanced NSCLC

Active, not recruiting

 Apatinib

D

NCT03164694

2

Si-yu Wang

First-line

Apatinib plus chemotherapy vs chemotherapy in ROS1 gene rearrangement advanced NSCLC

Recruiting

Targeting BRAF pathway

 BGB-283

D

CTR20150575

1

Lin-Shen

Second-line and beyond

Pharmacokinetics, safety, and tolerability in advanced solid tumor

Recruiting

  1. EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, HER2 human epidermal growth factor receptor-2, MET mesenchymal epithelial transition, VEGFR vascular endothelial growth factor receptor, PI principal investigator, I international, D domestic